Company: TVRD
Filing Date: 2025-10-20
Form Type: S-1/A
Source: 0001104659-25-100896
Chunk: 272

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-10-20
Form: S-1/A
Chunk 272
---
ments on the last day of each quarter, provided that the amount of such payment is prorated for any portion of such quarter that the director is not serving on our board of directors or applicable committee. The cash retainers are as follows: • Annual board retainer fee — $40,000 • Chairperson or Lead Independent Director (if any) fee — $30,000 • Audit Committee • Chairperson fee (including member fee) — $15,000

166

TABLE OF CONTENTS

•

Member fee — $7,500

•

Compensation Committee

•

Chairperson fee (including member fee) — $12,000

•

Member fee — $6,000

•

Nominating and Corporate Governance Committee

•

Chairperson fee (including member fee) — $10,000

•

Member fee — $5,000

Under the terms of the policy, we will also reimburse our non-employee directors for reasonable travel and out-of-pocket expenses incurred in connection with attending meetings of the board of directors and its committees.

Under the terms of the policy, our non-employee directors are also entitled to the following equity compensation:

•

Upon initial election or appointment to the board of directors, a stock option to purchase 12,000 shares of our common stock, with an exercise price equal to the fair market value of our common stock on the date of grant, with such option vesting over three years in 12 equal quarterly installments, subject to the director’s continued service as a director through each such vesting date.

•

On the date of each annual meeting of stockholders, for each continuing director, a stock option to purchase 6,000 shares of our common stock, with an exercise price equal to the fair market value of our common stock on the date of grant, with such option vesting on the earlier of (i) the one-year anniversary of the date of grant and (ii) immediately prior to the next annual meeting of stockholders following the date of grant, in each case, subject to the director’s continued service as a director through such date.

For 2025, directors will only receive an initial stock option grant.

<div align='center'>167</div>

TABLE OF CONTENTS

<div align='center'>**CERTAIN RELATIONSHIPS, RELATED PARTY AND OTHER TRANSACTIONS**</div>

Described below are any transactions occurring since January 1, 2023 and any currently proposed transactions, other than equity and other compensation, termination, change in control and other